
FDA approves phase 1/2 clinical trial with ABX196 in patients with liver cancer ABX196 to be tested in combination with checkpoint inhibitor nivolumab to treat hepatocellular carcinoma
May 14, 2019
LA JOLLA, CA The U.S. Food and Drug Administration has approved an investigational new drug (IND) application for a phase 1/2 clinical trial of ABX196, a liver cancer therapy developed in the laboratory of Scripps Research Professor Luc Teyton, MD, PhD, and licensed to French pharmaceutical company Abivax.
The FDA approval allows Abivax testing of ABX196 in patients with hepatocellular carcinoma (HCC), the most common form of liver cancer. ABX196 showed potent efficacy against HCC in preclinical testing.
The translation of basic research discoveries to the clinic is the greatest achievement we can hope for as clinician scientists. says Teyton, who is also a member of Abivax's Scientific Advisory Board. The use of ABX196 in the context of immunotherapy has been shown to be beneficial in multiple animal models of cancer, but the results with hepatocellular carcinoma are spectacular. We are looking forward to impacting the disease in patients, especially given the limitations of current therapies.
The open IND allows Abivax to test ABX196 in combination with nivolumab (Opdivo, Bristol-Myers Squibb), a checkpoint inhibitor, in a first phase 1/2 clinical trial to treat patients with HCC. The initial dose-escalation phase of the study will be conducted at the Scripps MD Anderson Cancer Center in San Diego, California, USA; additional leading cancer centers in the U.S. will be involved in the subsequent expansion phase of the study. The first patient is expected to be enrolled this summer.
We are thrilled to have been given the green light by FDA for our U.S. study. says Hartmut J. Ehrlich, MD, chief executive officer of Abivax. This open IND allows Abivax, in collaboration with leading key opinion leaders at internationally renowned U.S. cancer centers of excellence, to explore the clinical potential of our iNKT agonist ABX196 to broaden and potentiate the activity of the checkpoint inhibitor nivolumab. Based on its unique mechanism of action and exciting preclinical data in several cancer models, we believe ABX196 is a promising immunotherapeutic product candidate for patients with liver cancer that may also have potential in other cancers.
ABX196 is a synthetic glycolipid agonist of invariant natural killer T cells (iNKT) in a liposomal formulation. A phase 1 clinical trial conducted by Abivax in healthy volunteers has been completed and demonstrated safety and tolerability as well as a potent activation of iNKT cells. ABX196, both alone and in combination with a checkpoint inhibitor, showed a statistically highly significant therapeutic effect in reducing tumor growth as measured by MRI and increasing survival in mice with HCC. Abivax holds exclusive rights to ABX196 from Scripps Research, the University of Chicago, and Brigham Young University.
Despite the recent introduction of checkpoint inhibitors, hepatocellular carcinoma continues to be a substantial therapeutic challenge, as only about 20 percent of the treated patients show a response to these new drugs says Darren Sigal, MD, program director of GI Oncology at Scripps Clinic and Scripps MD Anderson Cancer Center in San Diego, and principal investigator of the study. While checkpoint inhibitors block a do not attack me' signal on cancer cells, ABX196 activates iNKT cells, a subpopulation of lymphocytes that is critical for mounting an effective immune response. The synergy between these two molecules carries substantial promise for improved outcomes for patients with this deadly cancer.
Checkpoint inhibitors like nivolumab are a leading class of therapeutic monoclonal antibodies that block certain endogenous proteins (PD-1/PDL-1) made by immune cells, such as T cells, as well as some cancer cells. These proteins effectively hijack the immune system, causing it to keep immune responses in check and preventing T cells from killing cancer cells. When these proteins are blocked, the brakes on the immune system are released and T cells are able to kill cancer cells much more efficiently. In some cancers, treatment with checkpoint inhibitors has been highly efficacious. However, due to the tumor micro-environment in other cancers, such as HCC, checkpoint inhibitors can have difficulties exerting their effects. ABX196 is intended as a drug that will potentiate the efficacy of checkpoint inhibitors by activating iNKT cells to kill tumor cells.
HCC is the most common form (75 to 90 percent) of primary liver cancer in adults. It typically occurs in the setting of chronic liver inflammation and/or cirrhosis and is closely linked to chronic viral infection such as hepatitis B or C, exposure to toxins such as alcohol, and to certain diseases such as non-alcoholic steatohepatitis (NASH).
The incidence of and deaths related to HCC are increasing in the United States and globally due to hepatitis B and C virus infections, as well as NASH. Prevalence data from 2018 show a total of 79,000 cases of HCC in the U.S. and G5 Europe (Germany, France, Italy, Spain and the UK), with 67,000 new cases, and a total of 260,000 cases in China with 338,000 new cases. Globally, there were 841,000 new cases of liver cancer (ranking it sixth of all reported cancers) and 782,000 fatalities (ranking it fourth) in 2018.
Currently, the American Cancer Society reports five-year survival rates in the U.S. of 31 percent for localized HCC, 11 percent for regional, and 2 percent for distant or metastatic, indicating a clear unmet medical need for improved therapies for HCC.
Cancer Immunology & Microbiology Teyton, Luc
Most recent headlines
05/01/2027
Worlds first 802.15.4ab-UWB chip verified by Calterah and Rohde & Schwarz to be ...
20/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
20/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
20/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
20/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
20/11/2026
Beam Dynamics has introduced new Model Context Protocol (MCP) support, expanding how customers can work with the live operational data held in Beam. The new cap...
20/11/2026
Re:Vision Effects Cyber Week Sale Nov 24 to Nov 30
Pierre Jasmin November 19, 2026
0 Comments
Long time friends of the COW are up with a big sale!
Us...
20/11/2026
Avid is offering up to 33% off annual subscriptions!
Brie Clayton November 19, 2026
0 Comments
Hero image courtesy Deposit Photos
Pro Tools
Pro To...
19/11/2026
With a sports-bar vibe and all the teams onsite in a huge atrium in Ballpark Vil...
19/11/2026
The senior from Phoenix and England is balancing life as a Division I tennis player with a growing career behind the microphone
The future of live sports produ...
19/11/2026
RED Digital Cinema and Colorfront have partnered to integrate native Colorfront color management into RED Connect, letting productions apply Colorfront's co...
19/11/2026
SMPTE has published an engineering report summarizing an industry survey by its Study Group on Content Provenance and Authenticity in Media. The findings point ...
19/11/2026
CTech and Skyline Communications have announced a partnership to deliver integra...
19/11/2026
Euskal Irrati Telebista (EITB), the Basque Country's public media group, has completed Phase 1 of a five-studio renewal with the commissioning of a Lawo IP ...
19/11/2026
The Esports Foundation (EF) has announced an expanded Road to ENC 2027 for the E...
19/11/2026
All Women's Sports Network (AWSN) held its first awards show, VEON: Women W...
19/11/2026
Gracenote, the content intelligence business unit of Nielsen, has extended its relationship with DIRECTV. Gracenote will continue to supply visual imagery and p...
19/11/2026
The Audio Engineering Society (AES) Technical Committee on Broadcast and Online ...
19/11/2026
NDI has released NDI 6.4, which adds Recording and Playback APIs, support for HEVC 4:4:4 and a configurable receiver buffer for Wi-Fi. The update also includes ...
19/11/2026
Lemonlight, the video production company behind more than 50,000 brand videos, has announced Hero, an AI production operating system, along with a new AI agent ...
19/11/2026
In a first-of-its-kind deployment at XFINITY Center, the digital signage/display...
19/11/2026
For the first time on a US streaming service, real-time player identification, contextual stats, and visual insights appear right in the live stream, available ...
19/11/2026
His career runs from the 2-in. videotape era to Canada's first HD and UHD live-production facilities...
19/11/2026
The popular sports-graphics event features a new Chairperson and new venue...
19/11/2026
Beth de Ara jo, Gemma Chan, Channing Tatum and Mason Reeves attend the premiere of Josephine at Eccles Theatre on January 23, 2026, in Park City, UT. (Photo b...
19/11/2026
New performance-focused brass library announced
Expressive E's latest release brings together four meticulously sampled brass instruments: sousaphone, b...
19/11/2026
Acoustic synthesizer gains free web editor
The phase8 acoustic synthesizer has been an ongoing project for Korg Berlin. It was unveiled as an early prototyp...
19/11/2026
MIDI controller keyboards upgraded
Designed for users who want a full-size keyboard and hands-on DAW control but in a relatively compact footprint, Nektar...
19/11/2026
Hugely popular compact monitor overhauled
IK Multimedia's ultra-compact monitors have proven to be incredibly popular, and the company say that they'...
19/11/2026
Rohde & Schwarz brings company-wide technology and service expertise to critical...
19/11/2026
On October 8, 2026, Nielsen employees came together around the world to celebrate our fourteenth company-wide day of service, Nielsen Global Impact Day (NGID). ...
19/11/2026
Integrating Gracenote's content intelligence with Nexxen's unique CTV supply allows advertisers to more closely align campaigns with audience viewing ha...
19/11/2026
Enhancement Mirrors Local TV's Recent Move to 1-Minute Qualifier (1MQ)
Upda...
19/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
19/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
19/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , er...
19/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
19/11/2026
As Founder and Creative Director of Future Phonic Studios, the Netherlands' first Dolby Atmos music studio, Richard Burki has spent more than a decade pushi...
19/11/2026
Boris FX Black Friday Sale - 25% Off Everything
Brie Clayton November 19, 2026
0 Comments
Check out the Boris FX Black Friday sale on Monday, November...
19/11/2026
Virtual Production Finds Its Middle Ground with Blackmagic Design
Brie Clayton November 19, 2026
0 Comments
How Neon Vision is using PYXIS 12K and Ult...
19/11/2026
FL Studio Announces Black Friday Discounts of Up to 50% Across Its Software Line...
19/11/2026
TBS Drama Series Tagusari Brothers Uses DaVinci Resolve Studio
Brie Clayton November 19, 2026
0 Comments
TBS ACT streamlines post production for broad...
19/11/2026
Beeble launches SwitchX 3.0 with dynamic environments and greater creative contr...
19/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
19/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...
19/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , er...
19/11/2026
Five-year deployment has automated APL's media supply chain from fixture to archive, managing over 200,000 assets
Blue Lucy, the workflow orchestration and...
19/11/2026
Riding the Australian wave through co-pros 11 November 2026
L-R: The Surfer, We Bury the Dead
Australian stories are captivating global audiences and attracti...
19/11/2026
Screen Australia and Australian Film Television and Radio School announce the Fi...
19/11/2026
Share
{alert(Link copied)}).catch(err => {console.error(Failed to copy: , err)}) data-platform=copy_link data-action= class=font-ui-heading py-2 text-sm tex...